These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 8914799)

  • 1. Adenovirus for neurodegenerative diseases: in vivo strategies and ex vivo gene therapy using human neural progenitors.
    Sabaté O; Barkats M; Buc-Caron MH; Castel-Barthe MN; Finiels F; Horellou P; Revah F; Mallet J
    Clin Neurosci; 1995-1996; 3(5):317-21. PubMed ID: 8914799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multipotent neural progenitor or stem-like cells may be uniquely suited for therapy for some neurodegenerative conditions.
    Snyder EY; Macklis JD
    Clin Neurosci; 1995-1996; 3(5):310-6. PubMed ID: 8914798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of ex vivo gene therapy in the treatment of Parkinson's disease.
    Raymon HK; Thode S; Gage FH
    Exp Neurol; 1997 Mar; 144(1):82-91. PubMed ID: 9126156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo adenovirus-mediated gene transfer for Parkinson's disease.
    Horellou P; Bilang-Bleuel A; Mallet J
    Neurobiol Dis; 1997; 4(3-4):280-7. PubMed ID: 9361305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transplantation to the rat brain of human neural progenitors that were genetically modified using adenoviruses.
    Sabaté O; Horellou P; Vigne E; Colin P; Perricaudet M; Buc-Caron MH; Mallet J
    Nat Genet; 1995 Mar; 9(3):256-60. PubMed ID: 7773288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A single adenovirus vector mediates doxycycline-controlled expression of tyrosine hydroxylase in brain grafts of human neural progenitors.
    Corti O; Sabaté O; Horellou P; Colin P; Dumas S; Buchet D; Buc-Caron MH; Mallet J
    Nat Biotechnol; 1999 Apr; 17(4):349-54. PubMed ID: 10207882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Towards gene therapy in the nervous system.
    Doering LC
    Clin Neurosci; 1995-1996; 3(5):259-61. PubMed ID: 8914791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The change of the neuron-glia differentiation rate in human neural precursor cells (HPCs) and Ad-BDNF-/-GDNF-infected HPCs following the administration of a neurotoxin.
    Yoo YM; Kim YJ; Lee U
    Neurosci Lett; 2005 Oct; 387(2):100-4. PubMed ID: 16081212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological, cell, and gene therapy strategies to promote spinal cord regeneration.
    Blits B; Boer GJ; Verhaagen J
    Cell Transplant; 2002; 11(6):593-613. PubMed ID: 12428749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adenovirus-mediated gene transfer to the central nervous system for Parkinson's disease.
    Horellou P; Sabaté O; Buc-Caron MH; Mallet J
    Exp Neurol; 1997 Mar; 144(1):131-8. PubMed ID: 9126162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of PEGylated adenovirus vector with targeting ligand.
    Eto Y; Yoshioka Y; Mukai Y; Okada N; Nakagawa S
    Int J Pharm; 2008 Apr; 354(1-2):3-8. PubMed ID: 17904316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Approaches to utilize mesenchymal progenitor cells as cellular vehicles.
    Pereboeva L; Komarova S; Mikheeva G; Krasnykh V; Curiel DT
    Stem Cells; 2003; 21(4):389-404. PubMed ID: 12832693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adenovirus-mediated transduction with human glial cell line-derived neurotrophic factor gene prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopamine depletion in striatum of mouse brain.
    Kojima H; Abiru Y; Sakajiri K; Watabe K; Ohishi N; Takamori M; Hatanaka H; Yagi K
    Biochem Biophys Res Commun; 1997 Sep; 238(2):569-73. PubMed ID: 9299553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of protamine to augment adenovirus-mediated cancer gene therapy.
    Lanuti M; Kouri CE; Force S; Chang M; Amin K; Xu K; Blair I; Kaiser L; Albelda S
    Gene Ther; 1999 Sep; 6(9):1600-10. PubMed ID: 10490770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene therapeutic strategies for neuroprotection: implications for Parkinson's disease.
    Bowers WJ; Howard DF; Federoff HJ
    Exp Neurol; 1997 Mar; 144(1):58-68. PubMed ID: 9126153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adenovirus-mediated GDNF and CNTF pretreatment protects against striatal injury following transient middle cerebral artery occlusion in mice.
    Hermann DM; Kilic E; Kügler S; Isenmann S; Bähr M
    Neurobiol Dis; 2001 Aug; 8(4):655-66. PubMed ID: 11493030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adenoviral gene therapy for cancer: from vectors to targeted and replication competent agents (review).
    Bauerschmitz GJ; Barker SD; Hemminki A
    Int J Oncol; 2002 Dec; 21(6):1161-74. PubMed ID: 12429964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune responses against adenoviral vectors and their transgene products: a review of strategies for evasion.
    Schagen FH; Ossevoort M; Toes RE; Hoeben RC
    Crit Rev Oncol Hematol; 2004 Apr; 50(1):51-70. PubMed ID: 15094159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-capacity 'gutless' adenoviral vectors.
    Kochanek S; Schiedner G; Volpers C
    Curr Opin Mol Ther; 2001 Oct; 3(5):454-63. PubMed ID: 11699889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer gene therapy using a novel secretable trimeric TRAIL.
    Kim CY; Jeong M; Mushiake H; Kim BM; Kim WB; Ko JP; Kim MH; Kim M; Kim TH; Robbins PD; Billiar TR; Seol DW
    Gene Ther; 2006 Feb; 13(4):330-8. PubMed ID: 16195699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.